Recent Updates
Recently added Catalysts

IMA-026

Phase 1

Healthy | Small molecule | Other |Pfizer, Inc.|Last Updated: Jul 23, 2009

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLEDBiomarker
Total Trials2
Total Enrollment100
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00528099Study Evaluating IMA-026 in Healthy Japanese MalesPHASE1 COMPLETED 50Oct 1, 2007Nov 1, 2008Jul 23, 20091 Japan
NCT00517348Study Evaluating IMA-026 in Healthy SubjectsPHASE1 COMPLETED 50Sep 1, 2007Jul 1, 2008Jun 25, 20091 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
To assess the safety and PK profile of IMA-026 administered as single ascending subcutaneous or intravenous doses.
6 months
Pharmacokinetic (PK) analysis
6 months
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelSINGLE_GROUP
PurposeTREATMENT
Interventions
NameTypeDescription
IMA-026DRUGSC and IV ascending single doses from lyophilized dosage form 0.3, 1, 2, 4 mg/kg SC and 3 mg/kg IV
Unlock Study Design Details
Eligibility Criteria
Age Range20 Years — 40 Years
SexMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Men ages 20 to 40 years, inclusive, at screening * Body mass index (BMI) in the range of 17.6 to 26.4 kg/m2 and body weight \> 45 kg * Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vitals sign...

Countries:JapanUnited States
Unlock Eligibility Criteria